Evidence map›Paper›PMID 36816598›Full record

ArticleThe World Allergy Organization journal2023

Latin American anaphylaxis registry.

Edgardo J Jares, Victoria Cardona, R Maximiliano Gómez, Jonathan A Bernstein, Nelson A Rosario Filho, Ivan Cherrez-Ojeda, Luis Felipe Ensina, Alicia De Falco, María C Díaz, Pierre A Chávez Vereau and 16 more

Open access · goldAbstract read
In one paragraph

Article in The World Allergy Organization journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Drug-Induced Anaphylaxis: National Database Analysis.Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 10 countries.

Edgardo J JaresAllergy Section, CMP S.A. LIBRA Foundation. Buenos Aires, Argentina.
Victoria CardonaAllergy Section, Hospital Universitari Vall D'hebron, Barcelona, Spain.
R Maximiliano GómezSchool of Health Sciences, Catholic University of Salta, Argentina.
Jonathan A BernsteinProfessor of Medicine University of Cincinnati, Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology. Cincinnati, USA.
Nelson A Rosario FilhoProfessor of Pediatrics, Federal University of Parana, Brazil.
Ivan Cherrez-OjedaRespiralab Research Center, Universidad Espiritu Santo, Samborondon, Ecuador.
Luis Felipe EnsinaFaaaai Affiliate Preceptor and Research Associate Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil.
Alicia De FalcoFacultad De Cs Médicas Dto Posgrado Universidad Nacional De La Plata Jefe Area Alergia E Inmunología Clínica, Hospital Español De La Plata, Argentina.
María C DíazHospital Pedro De Elizalde, Buenos Aires, Argentina.
Pierre A Chávez VereauClínica Internacional, Universidad Peruana De Ciencias Aplicadas, Lima, Peru.
Mara M Rocha FelixProfessor of Allergy and Immunology, Universidade Federal Do Estado Do Rio De Janeiro, Brazil.
Jorge LavrutHospital Pedro De Elizalde, Buenos Aires, Argentina.
Oscar I Moreno LaflorAllergy and Clinical Immunology Department, Hospital Infantil De México Federico Gómez, Mexico.
Patricia Latour StaffeldUniversidad Nacional Pedro Henriquez Ureña, Centro Avanzado De Alergia Y Asma. Santo Domingo, Dominican Republic.
Pedro PirainoUniversidad Católica Ntra. Señora De La Asunción, Paraguay.
Perla Alacaraz DuarteUniversidad Nacional De Asunción, Paraguay.
Juan C IvancevichAssociate Professor of Immunology, Faculty of Medicine, Universidad Del Salvador, Buenos Aires, Argentina.
Fabian DaboveCemlo- Research Center Director, Lobos, Argentina.
Pedro Giavina-BianchiAssociate Professor Clinical Immunology and Allergy Division, Universidade De São Paulo, São Paulo, Brazil.
Iván O Tinoco MoranRespiralab, Guayaquil, Ecuador.
Fabiana A Nunes OlivieraDivision of Allergy and Clinical Immunology, Federal University of São Paulo (Unifesp), São Paulo, Brazil.
Silvana MonsellFundación Libra. Facultad De Medicina Universidad De Buenos Aires. Buenos Aires, Argentina.
María V SouzaHospital Pedro De Elizalde, Buenos Aires, Argentina.
Alfonso M CepedaClinical Allergy - Pediatric Allergy Fundación Hospital Universitario Metropolitano Universidad Metropolitana Barranquilla, Colombia.
Pablo D SlullitelHospital Pedro De Elizalde Buenos Aires, Argentina.
Blanca M Morfin-MacielFaaaai Hospital San Angel Inn Chapultepec, Ciudad De México, Mexico.
Hospital Pedro de Elizalde · ARUniversidade Federal de São Paulo · BRConsejo Nacional de Investigaciones Científicas y Técnicas · ARFavaloro Foundation · ARHospital Infantil de México Federico Gómez · MXHospital Italiano La Plata · ARPeruvian University of Applied Sciences · PEUniversidad Católica de Salta · ARUniversidad Católica Nuestra Señora de la Asunción · PYUniversidad Chapultepec · MXUniversidad de Buenos Aires · ARUniversidad de Especialidades Espíritu Santo · ECUniversidad del Salvador · ARUniversidade Brasil · BRUniversidade Federal do Estado do Rio de Janeiro · BRUniversidade Federal do Paraná · BRUniversidad Metropolitana · COUniversidad Nacional de Asunción · PYUniversidad Nacional Pedro Henríquez Ureña · DOUniversity of Cincinnati · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recent data about clinical features, triggers and management of anaphylaxis in Latin America is lacking. Objective: To provide updated and extended data on anaphylaxis in this region. Method: An online questionnaire was used, with 67 allergy units involved from 12 Latin-American countries and Spain. Among data recorded, demographic information, clinical features, severity, triggering agents, and treatment were received. Results: Eight hundred and seventeen anaphylactic reactions were recorded. No difference in severity, regardless of pre-existing allergy or asthma history was found. Drug induced anaphylaxis (DIA) was most frequent (40.6%), followed by food induced anaphylaxis (FIA) (32.9%) and venom induced anaphylaxis (VIA) (12%). FIA and VIA were more common in children-adolescents. Non-steroidal anti-inflammatory drugs (NSAIDs) and beta-lactam antibiotics (BLA) were the most frequent drugs involved. Milk (61.1% of FIA) and egg (15.4% of FIA) in children, and shellfish (25.5% of FIA), fresh fruits (14.2% of FIA), and fish (11.3% of FIA) in adults were the most common FIA triggers. Fire ants were the most frequent insect triggers, and they induced more severe reactions than triggers of FIA and DIA (p < 0.0001). Epinephrine was used in 43.8% of anaphylaxis episodes. After Emergency Department treatment, epinephrine was prescribed to 13% of patients. Conclusions: Drugs (NSAIDs and BLA), foods (milk and egg in children and shellfish, fruits and fish in adults) and fire ants were the most common inducers of anaphylaxis. Epinephrine was used in less than half of the episodes emphasizing the urgent need to improve dissemination and implementation of anaphylaxis guidelines.

Indexed as

AnaphylaxisFood hypersensitivityInsect venom hypersensitivityLatin AmericaMedication hypersensitivity

Identifiers

PMID36816598
PMCPMC9936519
OpenAlexW4319264391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.